Chengdu Easton Biopharmaceuticals (688513) Fundamentals 2026 — P/E 34.1x, Revenue Analysis | SniperIQ
Chengdu Easton Biopharmaceuticals (688513) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥9.5B, trading at ¥53.90 on the SHH. This SniperIQ fundamentals page covers Chengdu Easton Biopharmaceuticals's valuation (P/E 34.1x, P/B 3.1x), profitability (net margin 20.3%), revenue (¥1.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Chengdu Easton Biopharmaceuticals's market cap?
Chengdu Easton Biopharmaceuticals (688513) has a market capitalization of approximately ¥9.5B, trading at ¥53.90 on the SHH. Market cap moves with the live share price.
What is Chengdu Easton Biopharmaceuticals's P/E ratio?
Chengdu Easton Biopharmaceuticals's trailing twelve-month P/E ratio is 34.1x, with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Chengdu Easton Biopharmaceuticals?
Chengdu Easton Biopharmaceuticals runs a net profit margin of 20.3%, a gross margin of 74.4%, and an operating margin of 20.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Chengdu Easton Biopharmaceuticals generate?
Chengdu Easton Biopharmaceuticals reported revenue of ¥1.3B for fiscal year 2025, with net income of ¥284M and earnings per share (EPS) of 1.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Chengdu Easton Biopharmaceuticals pay a dividend?
Chengdu Easton Biopharmaceuticals offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Chengdu Easton Biopharmaceuticals financially healthy?
Chengdu Easton Biopharmaceuticals carries a debt-to-equity ratio of 0.04x and a current ratio of 3.82x, with a market beta of 0.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Chengdu Easton Biopharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chengdu Easton Biopharmaceuticals (688513) the key facts are: market cap ¥9.5B, P/E 34.1x, revenue ¥1.3B, 52-week range 40.25-80.48. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Chengdu Easton Biopharmaceuticals's full fundamentals live
Get Chengdu Easton Biopharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.